alintegimod (7HP349)

News alerts, weekly reports and conference planners

Company:

7 Hills Pharma

Drug class:

α4β1 activator, αLβ2 activator

‹

›

over1year

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy (clinicaltrials.gov)

P1/2, N=126, Recruiting, 7 Hills Pharma, LLC | Not yet recruiting --> Recruiting

over 1 year ago

Enrollment open • Combination therapy • Metastases

Opdivo (nivolumab) • Yervoy (ipilimumab) • alintegimod (7HP349)

almost2years

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy (clinicaltrials.gov)

P1/2, N=126, Not yet recruiting, 7 Hills Pharma, LLC

almost 2 years ago

New P1/2 trial • Combination therapy • Metastases

Opdivo (nivolumab) • Yervoy (ipilimumab) • alintegimod (7HP349)

over3years

LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. (PubMed, J Clin Invest)

Here, we show that 7HP349, a small-molecule activator of lymphocyte function-associated antigen-1 (LFA-1) and very late activation antigen-4 (VLA-4) integrin cell-adhesion receptors, facilitated the preferential localization of tumor-specific T cells to the tumor and improved antitumor response...We identified baseline CXCL12 gene expression may improve response likelihood to anti-CTLA-4 therapies. Our results provided a proof-of-principle demonstration that LFA-1 activation could convert a T cell-exclusionary TME to a T-cell enriched TME through mechanisms involving cooperation with innate immune cells.

over 3 years ago

Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • CXCL12 (C-X-C Motif Chemokine Ligand 12)

CXCL12 expression

alintegimod (7HP349)